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SUMMARY
We evaluated the immunogenicity of three recombinant hepatitis B vaccines, one Brazilian (Butang, Instituto Butantan) and two
Korean vaccines (Euvax-B, LG Chemical Ltd. and Hepavax-Gene, Greencross Vaccine Corp.), administered intramuscularly to students
aged 17 to 19 years in three 10-µg doses (corresponding to half the amount of antigen routinely used for adult vaccination) at intervals
of one month between the first and second dose, and of four months between the second and third dose. A total of 316 students non-
reactive for any serological marker of hepatitis B virus infection were vaccinated: 77 (24.4%) with the Butang vaccine, 71 (22.5%)
with Euvax-B, 85 (26.9%) with Hepavax-Gene and, for comparison, 83 (26.2%) with Engerix-B (GlaxoSmithKline), whose efficacy
in young adults at the dose used here has been confirmed in previous studies. Similar seroconversion rates (anti-HBs > 10 mIU/mL
about one month after application of the third dose) were obtained for the Butang, Euvax-B, Hepavax-Gene and Engerix-B vaccines
(96.2%, 98.6%, 96.5% and 97.6%, respectively). The frequency of good responders (anti-HBs > 100 mIU/mL) was also similar
among students receiving the four vaccines (85.8%, 91.6%, 89.4% and 89.2%, respectively). The geometric mean titers (GMT) of
anti-HBs about one month after the third dose obtained with these vaccines were 727.78 ± 6.46 mIU/mL, 2009.09 ± 7.16 mIU/mL,
1729.82 ± 8.85 mIU/mL and 2070.14 ± 11.69 mIU/mL, respectively. The GMT of anti-HBs induced by the Euvax-B and Engerix-B
vaccines were higher than those obtained with the Butang vaccine (p < 0.05); this difference was not significant when comparing the
other vaccines two-by-two. No spontaneous adverse effects attributable to the application of any dose of the four vaccines were
reported.
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INTRODUCTION
Recombinant vaccines against hepatitis B licensed in Brazil by the
Ministry of Health possess widely confirmed immunogenicity when
applied in the schemes standardized by the “Programa Nacional de
Imunizações” (National Immunization Program, NIP). In the case of
some of these vaccines (Engerix-B, GlaxoSmithKline, and Recombivax,
Merck Sharp & Dohme), it has been demonstrated that half the dose
usually indicated for adults yields similar seroconversion rates in persons
younger than 20 years2,3,7,8,10. However, no studies are available
demonstrating the immunogenicity of other recombinant hepatitis B
vaccines with a similar composition and obtained by the same methods
when the same dose is applied to individuals aged 12 to 19 years.
In a message sent on January 1, 2001 to the State Coordinators, the
General Coordination Board of the Immunization Program of the
National Health Foundation of the Ministry of Health communicated
that “the present hepatitis B vaccine scheme recommended by the NIP
is 10 µg in 0.5 mL (Engerix-B - SmithKline Beecham) for individuals
from birth until 20 years of age”. Since the Ministry of Health intends to
recommend the use of other recombinant hepatitis B vaccines available
through the NIP for this age group at this dose (which corresponds to
half the antigen amount indicated for adults) – using the same scheme of
three doses administered intramuscularly at an interval of one month
between the first and second dose and of five months between the second
and third –, assessment of the immunogenicity of this vaccination scheme
for another recombinant vaccines in individuals younger than 20 years
becomes necessary.
The objective of the present study was to determine the
immunogenicity of three recombinant hepatitis B vaccines available
through the NIP in susceptible individuals younger than 20 years, by
administering intramuscularly three doses containing half the amount
of antigen habitually employed in adult vaccination using a scheme
similar to that adopted by the NIP.
104
BALDY, J.L.S.; LIMA, G.Z.; MORIMOTO, H.K.; REICHE, E.M.V.; MATSUO, T.; MATTOS, E.D. & SUDAN, L.C.P. - Immunogenicity of three recombinant hepatitis B vaccines administered
to students in three doses containing half the antigen amount routinely used for adult vaccination. Rev. Inst. Med. trop. S. Paulo, 46(2):103-107, 2004.
PATIENTS AND METHODS
The study was conducted during the period from February 2001 to
April 2002 on students enrolled in first-year courses given at Universidade
Estadual de Londrina (UEL), located in the municipality of Londrina,
Paraná, Brazil, and at Universidade Norte do Paraná (UNOPAR), which
comprises four campuses, three located in the municipality of Londrina
and one in the municipality of Arapongas, 39 km from Londrina.
The following recombinant hepatitis B vaccines were included in
the study: Butang (Instituto Butantan, Brazil), Euvax-B (LG Chemical
Ltd., Korea), Hepavax-Gene (Greencross Vaccine Corp., Korea) and,
for comparison of the results, Engerix-B (GlaxoSmithKline, England),
whose immunogenicity in individuals aged 11 to 19 years has already
been demonstrated by applying half the dose used for adults in a three-
dose scheme (0, 1, and 6 month scheme)2,7,10.
The study was approved by the Research Ethics Committee of
Hospital Universitário Regional do Norte do Paraná, UEL, and by the
Research Board of the Research and Postgraduation Coordination
Committee of this University, with these decisions being approved by
the Nursing President’s Office and Board of UNOPAR.
The proposal of the study was to administer intramuscularly in the
deltoid region one of the four vaccines in three 10 µg doses in a volume
of 0.5 mL (with 20 µg in 1.0 mL corresponding to the amount of antigen
used for adult vaccination for all vaccines) to 100 students using a 0, 1,
and 5 month scheme. Assuming that the efficacy of these vaccines
(seroconversion) is at least 90% and that the difference in the number of
students included in each group is not higher than 10%, the minimum
number of students to be vaccinated, i.e., who should receive each
vaccine, was calculated to be 71 per group using the statistical methods
mentioned at the end of this section. Due to contingencies related to the
dates of the academic year and vacation periods of the students, a 0, 1,
and 5-month vaccination scheme was chosen (similar to the 0, 1, and 6-
month scheme officially adopted by the NIP).
All students younger than 20 years enrolled in UEL and UNOPAR
courses received a written invitation to participate in the study and to
attend the lectures on hepatitis B and on the importance of vaccination
against this disease given by the authors.
The students who adhered to the study answered a standard
questionnaire containing data regarding identification, address, a history
of hepatitis (hepatitis B in particular), hepatitis B vaccination, blood
donation, blood transfusion during the previous six months, other
diseases, and continuous drug treatment.
Students who declared to be younger than 20 years and who signed
an informed consent form were included in the study. The reported age
was confirmed by presentation of an identification document at the time
of application of the first or second vaccine dose, with individuals who
had completed 20 years at the time of application of the first dose being
excluded from the study. Also excluded were students who had been
vaccinated at least once against hepatitis B, individuals with chronic
debilitating disease, diabetes mellitus, anemia, chronic renal failure or
some type of immunodepression, and students taking corticosteroids
and/or other immunosuppressive drugs. After the students had answered
the questionnaire and blood was collected, the subjects were asked to
choose a card from a randomly mixed pack of cards previously identified
by an equal number of the letters A, B, C and D, each corresponding to
one of the four vaccines. Only two researchers knew which letter
corresponded to which vaccine, but none of them participated in the
serological tests or statistical analysis of the results; the vaccine code
was only revealed to the entire research team at the beginning of the
preparation of the report for the present article.
Immediately before application of the first vaccine dose, 5 ml blood
was collected from the vein of the anterior side of the forearm from all
students included in the study for determination of the following markers
of hepatitis B virus infection: HBsAg, anti-HBs and anti-HBc using a
microparticle enzyme immunoassay (MEIA; Axsym Abbott). Students
who were reactive to HBsAg and/or anti-HBc were referred for
specialized medical evaluation and anti-HBs-positive individuals were
considered to be immune and received a detailed explanation about why
they did not require vaccination.
Thus, before application of the second dose, with the results of the
serological tests being available, students who were found to be positive
for at least one of the cited markers (anti-HBs, HBsAg or anti-HBc)
were excluded. During the study, individuals who did not return for
application of the second or third dose or for collection of the second
blood sample were also excluded.
One month after application of the third vaccine dose, a second
venous blood sample was collected from all vaccinees for a new
determination of the same serological markers of hepatitis B virus
infection (HBsAg, anti-HBs and anti-HBc) by the same technique (MEIA,
Axsym Abbott). Anti-HBs titers were interpreted based on data reported
in the literature5,6: < 10 mIU/mL = non-reactive (non-responders); ≥ 10
mIU/mL = reactive; 10 to 100 mIU/mL = reactive (poor responders) and
> 100 mIU/mL = reactive (good responders).
All vaccinated students were asked to inform one of the coordinators
of the study about local (pain, local redness or nodule formation) or
systemic adverse effects (fever, headache or any other symptom), which
occurred after application of the vaccine (in the case of intense local
pain, fever or headache, the students were instructed to take 30 drops of
paracetamol every 6 hours until they would contact one of the
researchers). On the occasion of a return for receiving the new vaccine
dose or for collection of the second blood sample, the students were also
asked to inform the team about the occurrence of signs and symptoms
attributable to vaccination.
Serum geometric mean titers (GMT) of anti-HBs obtained for each
vaccine group, quantified about one month after the vaccination scheme
was completed, were compared by analysis of variance, using the F-test
to determine the equality of means. When a significant difference was
observed between titers, the Tukey test was used for pairwise comparison
of the GMT obtained for each vaccine. The relative frequencies of good
and poor responders to the vaccines were compared by Pearson’s chi-
square test. The level of significance adopted for all tests was 5% (p <
0.05). The statistical analyses were performed using the SAS – Statistical
Analysis System program (SAS Institute Inc., 1986)9 and the sample
size was determined using the nQuery Advisor program4.
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RESULTS
The present study included 955 students, 248 from UEL and 707
from UNOPAR; 615 (64.4%) were females and 339 (35.5%) were males.
Of the 955 students who underwent the serological tests, one (0.1%)
showed HBsAg at a low titer and was not reactive to anti-HBc, 37 (3.9%)
were positive for serum anti-HBs (11 of them were also positive for
anti-HBc, i.e., anti-HBs alone was detected in 26), and two (0.2%) were
positive for serum anti-HBc. These 40 students were excluded from the
group to be vaccinated. A new blood sample for repetition of the
serological tests was obtained from the student who showed a weak
reaction to HBsAg and who was negative for anti-HBc. The following
individuals were also excluded: 219 students who failed to return on the
day of application of the second (53 students) and third (166 students)
vaccine dose; 115 students who received the three doses but failed to
return for collection of the second blood sample about one month after
the third vaccine dose; four students whose vaccine type applied in the
first dose could not be identified due to the lack of information on the
individual chart; 13 because of age (it was confirmed during the study
that these individuals had already completed 20 years on the day of
application of the first dose), and 259 students initially selected to receive
the total dose (20 µg) of the Engerix-B (133 students selected by drawing
lots) and Butang vaccines (126 students selected by drawing lots), most
of them (177) enrolled at the Arapongas campus of UNOPAR. Most
students from this campus did not respond to the invitation due to vacation
periods and, therefore, the minimum number of participants required
for these two groups (71 per group) was not reached. For this reason, the
three 20 µg dose regimen was not evaluated and the 259 students were
excluded from the study. It should be noted that 11 of these 259 students
were among the 40 individuals excluded due to the reason mentioned at
the beginning of this paragraph. In addition, 190 of the 248 students
from UEL who received the first vaccine dose were excluded, i.e., only
58 completed the study, because of the strike of teachers and technical-
administrative employees of this university which lasted throughout the
study. In summary, 639 (66.9%) of the 955 initially selected students
were excluded from the study due to the reasons mentioned earlier.
Vaccination against hepatitis B was indicated for 915 students who
were negative for all serological markers tested and who orally declared
to be younger than 20 years on the day of application of the first vaccine
dose. Initially, four groups of these students were selected by drawing
lots in order to receive the three 10 µg doses of the following vaccines:
Butang (N =167), Euvax-B (N = 176), Hepavax-Gene (N = 176), and
Engerix-B (N = 173). Due to the reasons mentioned earlier, only 316 of
these students received the three 10 µg doses of the vaccines and were
submitted to serological tests about one month after application of the
third dose, including 258 (81.6%) students from UNOPAR and 58
(18.4%) from UEL. Twenty-one (6.6%) students were 17 years old, 126
(39.9%) 18 years old, and 169 (53.5%) 19 years old. The mean age of
the vaccinees was 18.5 ± 0.62 years; 223 (70.6%) were females and 93
(29.4%) were males. Table 1 shows the distribution of the students
according to the vaccine received.
The interval between application of the first and second dose ranged
from 26 to 37 days for all vaccines, with a mean of 32.6 ± 2.48 days.
The interval between application of the second and third dose ranged
from 96 to 149 days for all vaccines (121.1 ± 4.02 days). The interval
between application of the third dose and collection of the second blood
sample for the serological tests ranged from 23 to 51 days for all vaccines
(29.6 ± 4.46 days).
HBsAg and anti-HBc were not detected in the second serum sample
of vaccinated individuals who presented seroconversion (serum anti-
HBs titers ≥ 10 mIU/mL).
The vaccinees did not report any spontaneous complaints regarding
local or systemic adverse effects after each vaccine application.
Table 2 shows the distribution of students receiving the different
vaccines according to serum anti-HBs titers about one month after the
application of the third dose.
Results obtained with the Butang vaccine: The interval between
application of the first and second Butang dose ranged from 28 to 37
Table 2
Distribution of the students who received the Butang, Euvax-B, Hepavax-Gene and Engerix-B vaccines according to serum anti-HBs titers one month after the
third dose
Serum anti-HBs titer Butang Euvax-B Hepavax-Gene Engerix-B
after the third dose
(mIU/mL) n % n % n % n %
< 10 3 3.8 1 1.4 3 3.5 2 2.4
10 |—| 100 8 10.4 5 7.0 6 7.1 7 8.4
100 —| 1000 28 36.4 19 26.8 18 21.2 19 22.9
> 1000 38 49.4 46 64.8 58 68.2 55 66.3
Total 77 100.0 71 100.0 85 100.0 83 100.0
Table 1
Student distribution according to the vaccine administered
Vaccine applied Vaccinated students
N %
Butang (Instituto Butantan, Brasil) 77 24.4
Euvax-B (LG Chemical Ltd., Korea) 71 22.5
Hepavax-Gene (Greencross 85 26.9
Vaccine Corp., Korea)
Engerix-B (GlaxoSmithKline, England) 83 26.2
Total 316 100.0
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days (33.2 ± 2.05), the interval between application of the second and
third dose ranged from 117 to 139 days (120.5 ± 2.88), and the interval
between application of the third dose and collection of the second blood
sample ranged from 23 to 44 days (28.8 ± 3.07). The GMT of anti-HBs
in students who received this vaccine was 727.78 ± 6.46 mIU/mL.
Results obtained with the Euvax-B vaccine: The interval between
application of the first and second Euvax-B dose ranged from 27 to 37
days (32.1 ± 2.65), the interval between application of the second and
third dose ranged from 96 to 139 days (121.3 ± 5.01), and the interval
between application of the third dose and collection of the second blood
sample ranged from 23 to 51 days (30.7 ± 5.76). The GMT of anti-HBs
in students who received this vaccine was 2009.09 ± 7.16 mIU/mL.
Results obtained with the Hepavax-Gene vaccine: The interval
between application of the first and second Hepavax-B dose ranged from
27 to 35 days (32.5 ± 2.58), the interval between application of the
second and third dose ranged from 118 to 138 days (121.1 ± 3.32), and
the interval between application of the third dose and collection of the
second blood sample ranged from 23 to 49 days (29.6 ± 4.00). The
GMT of anti-HBs in students who received this vaccine was 1729.82 ±
8.85 mIU/mL.
Results obtained with the Engerix-B vaccine: The interval between
application of the first and second Engerix-B dose ranged from 26 to 36
days (32.7 ± 2.53), the interval between application of the second and
third dose ranged from 118 to 149 days (121.4 ± 4.59), and the interval
between application of the third dose and collection of the second blood
sample ranged from 23 to 49 days (29.6 ± 4.62). The GMT of anti-HBs
in students who received this vaccine was 2070.14 ± 11.69 mIU/mL.
Comparison of the results obtained with the four vaccines: Table
3 shows the distribution of students who received the four vaccines
according to serum anti-HBs titers about one month after administration
of the third dose. The seroconversion rate, and GMT and standard deviation
of serum anti-HBs about one month after application of the third dose
obtained with three 10 µg doses of the four vaccines studied (0, 1, and 5
month scheme) are shown in Table 4. Statistical analysis of log transformed
data demonstrated higher GMT of anti-HBs in students vaccinated with
the Euvax-B and Engerix-B vaccines when compared pairwise than those
induced with the Butang vaccine (p < 0.05), while pairwise comparison
of the other vaccines showed no differences in GMT of anti-HBs.
A similar frequency of good responders (anti-HBs > 100 mIU/mL)
was observed for all four vaccines studied (p > 0.05).
DISCUSSION AND CONCLUSION
No investigations are available in the literature evaluating the
immunogenicity of the three recombinant vaccines studied here – one
Brazilian vaccine (Butang, Instituto Butantan, São Paulo, Brazil) and
two Korean ones (Euvax-B, LG Chemical Ltd., Korea, and Hepavax-
Gene, Greencross Vaccine Corp., Korea) - in adolescents and young
adults administered in three 10 µg doses, corresponding to half the dose
recommended for routine use in adults, using 0, 1, and 6 month or 0, 1,
and 5-month schemes. The immunogenicity of three doses of other
recombinant hepatitis B vaccines (including the Engerix-B vaccine from
GlaxoSmithKline, England), administered intramuscularly and
containing half the antigen amount indicated for adults (0, 1, and 6 month
scheme), has been demonstrated in children, adolescents and young
adults2,3,7,8,10 and their use has been recommended by the American
Academy of Pediatrics1.
In the present study, in which the three cited vaccines were
administered intramuscularly to hepatitis B-susceptible university
students between the ages of 17 and 19 (three 10 µg doses; 0, 1, and 5-
month scheme), immunogenicity was demonstrated for all of them, with
seroconversion being obtained about one month after the third dose in
more than 96% of the vaccinees: 96.2%, 98.6% and 96.5% for students
receiving the Butang, Euvax-B and Hepavax-Gene vaccines, respectively.
A similar seroconversion rate (97.6%) was obtained with the Engerix-B
vaccine used for comparison. Among the students presenting
seroconversion, 85.8%, 91.6%, 89.4% and 89.2% of those receiving the
Butang, Euvax-B, Hepavax-Gene and Engerix-B vaccine, respectively,
were considered to be good responders (anti-HBs > 100 mIU/mL about
one month after vaccination was completed), with no significant
difference between students receiving the four vaccines. The GMT of
anti-HBs observed in the vaccinees was 1520.55 mIU/mL. In a similar
study in which three 10 µg doses of Engerix-B were administered
intramuscularly to individuals aged 11 to 19 years in a 0, 1, and 6-month
scheme, the GMT was 1988.8 mIU/mL one month after application of
the third dose10. The GMT for the Euvax-B and Engerix-B vaccines were
higher than that obtained for the Butang vaccine, but this difference was
Table 3
Distribution of all students who received the four vaccines according to serum
anti-HBs titers about one month after the third dose
Anti-HBs titer Vaccinated students
(mIU/mL) N %
< 10 9 2.8
10 |—| 100 26 8.2
100 —| 1000 84 26.6
> 1000 197 62.3
Total 316 100.0
Table 4
Seroconversion rate, geometric mean titer (GMT) and standard deviation of
anti-HBs one month after application of three 10 µg doses (0, 1, and 5 month
scheme) of four recombinant hepatitis B vaccines
Vaccine studied Seroconversion GMT Standard
rate (mIU/mL) deviation
%  (mIU/mL)
Butang 96.2 727.78 6.46
(n = 77)
Euvax-B 98.6 2009.09 7.16
(n = 71)
Hepavax-Gene 96.5 1729.82 8.85
(n = 85)
Engerix-B 97.6 2070.14 11.69
(n = 83)
Overall mean 97.2 1520.55 8.79
(n = 316)
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not observed when pairwise comparisons of these vaccines were
performed. We are unable to explain why the GMT for the Butang vaccine
was lower than that obtained for the other two vaccines.
No spontaneous adverse effects attributable to the application of any
vaccine dose were reported by the vaccinated students.
In conclusion, the present results demonstrated a similar, highly
satisfactory immunogenicity of the three recombinant hepatitis B vaccines
(Butang, Euvax-B and Hepavax-Gene) used in healthy 17- to 19-year-
old individuals when applying the dose, route and scheme reported here,
equivalent to that of the Engerix-B vaccine, although the GMT of the
anti-HBs obtained for the Butang vaccine was significantly lower than
the GMT obtained for the Engerix-B and Euvax-B vaccines. The
possibility to use half the vaccine dose in adolescents with the same
efficacy and safety leads to a significant reduction in the cost of hepatitis
B vaccination and opens promising perspectives for the adoption of the
same conduct in children (i.e., application of the three recombinant
vaccines studied at half the dose routinely used for persons older than
19 years), considering that, with respect to two recombinant vaccines
used at our institutions (Engerix-B, GlaxoSmithKline and Recombivax,
Merck, Sharp & Dohme), the reduced dose (10 µg and 5 µg, respectively)
is already indicated for newborns, children and adolescents1.
RESUMO
Imunogenicidade de três vacinas recombinantes contra hepatite B
administradas a estudantes em três doses contendo 50%
da quantidade de antígeno usada rotineiramente para a
vacinação de adultos
Avaliou-se neste estudo a imunogenicidade de três vacinas
recombinantes contra a hepatite B (HB), uma brasileira (Butang, do
Instituto Butantan) e duas coreanas (Euvax-B, da LG Chemical Ltd. e
Hepavax-Gene, da Greencross Vaccine Corp.), administradas a jovens com
17 a 19 anos, por via intramuscular, em três doses de 10 µg (que
correspondem a 50% da quantidade do antígeno contida na vacina usada
rotineiramente em adultos), com intervalos de um mês entre a primeira e
a segunda, e de quatro meses entre a segunda e a terceira doses. Foram
vacinadas 316 pessoas nas quais não foi encontrado nenhum marcador
sorológico de infecção pelo vírus da HB: 77 (24,4%) com a Butang, 71
(22,5%) com a Euvax-B, 85 (26,9%) com a Hepavax-Gene e, para
comparação, 83 (26,2%) com a Engerix-B. A eficiência da vacina
recombinante contra a hepatite B produzida pela GlaxoSmithKline
(Engerix-B), em adultos jovens, na dose que usamos, já tinha sido
comprovada em pesquisas anteriormente realizadas. Neste estudo, as taxas
de soroconversão (anti-HBs > 10 mUI/mL, cerca de um mês depois da
terceira dose) obtidas com as vacinas Butang, Euvax-B, Hepavax-Gene e
Engerix-B foram semelhantes, iguais respectivamente a 96,2%, 98,6%,
96,5% e 97,6%. A freqüência de bons respondedores (anti-HBs > 100
mUI/mL) foi também semelhante entre os que receberam as quatro vacinas
(85,8%, 91,6%, 89,4% e 89,2%, respectivamente). A média geométrica
dos títulos séricos de anti-HBs obtidos cerca de um mês depois da terceira
dose, com essas vacinas, foi igual a 727,78 ± 6,46 mUI/mL, 2.009,09 ±
7,16 mUI/mL, 1.729,82 ± 8,85 mUI/mL e 2.070,14 ± 11,69 mUI/mL,
respectivamente. As médias geométricas dos títulos séricos de anti-HBs
induzidos pela Euvax-B e pela Engerix-B foram maiores que a média
geométrica do título sérico de anti-HBs induzido pela Butang (p < 0,05);
essa diferença não foi estatisticamente significativa quando se compararam,
duas a duas, as outras vacinas. Não se registrou nenhuma queixa espontânea
dos vacinados sobre eventos adversos que tivessem atribuído à aplicação
de qualquer dose das quatro vacinas.
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